KROS, ASND, GOSS: Biopharma Stocks To Watch In 2024

Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company that develops therapies for hematologic and cardiovascular disease. Wedbush’s Andreas Argyrides breaks down the biopharma space, as Wedbush has an outperform rating and an $86 price target on KROS. He also talks about Asecndis Pharma (ASND) which is on Wedbush’s top picks for 2024. He then goes over Gossamer Bio (GOSS) which is developing Seralutinib (GB002) for the treatment of PAH. Tune in to find out more about the stock market today.

Market On Close

21 Dec 2023

SHARE

ON AIR
1:30 pm
Trading 360
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Trading 360
REPLAY
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
9:30 am
Market Overtime
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
ON AIR
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now